Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical stage biotechnology company focused on developing therapeutics for patients with inflammatory bowel disease (IBD) and rheumatic diseases. Its pipeline includes several monoclonal antibody programs: SPY001, a humanized anti-a4ß7 integrin antibody in phase-2 for ulcerative colitis and Crohn's disease; SPY002 and SPY072, anti-TL1A antibodies targeting tumor necrosis factor-like ligand 1A; and SPY003, an anti-IL-23 antibody also in phase-2. The company is also developing combination therapies such as SPY120 (anti-a4ß7 + anti-TL1A), SPY130 (anti-a4ß7 + anti-IL-23), and SPY230 (anti-TL1A + anti-IL-23). These products aim to address key inflammatory pathways in IBD and related conditions.

Spyre Therapeutics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SYRE. Its shares are traded in United States Dollars (USD), which is the official currency of the United States. As a Nasdaq-listed company, it is subject to the reporting and governance requirements of the U.S. Securities and Exchange Commission (SEC). Investors can buy and sell SYRE shares through most brokerage platforms that offer access to U.S. stock exchanges.

Spyre Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use living organisms or their derivatives to develop drugs and therapies. Spyre focuses on monoclonal antibodies and combination biologics for inflammatory diseases, which is a common area in biotech. The company is classified as a clinical-stage biotech, meaning it has not yet commercialized any products and is primarily engaged in research and development activities. Its work targets autoimmune and inflammatory conditions like ulcerative colitis, Crohn's disease, and rheumatic diseases.

Spyre Therapeutics is headquartered in Waltham, Massachusetts, United States. The company was originally incorporated in 2013 under the name Aeglea BioTherapeutics, Inc. It rebranded to Spyre Therapeutics, Inc. in November 2023, signaling a strategic shift toward inflammatory bowel disease and rheumatic disease therapies. The company's operations are based in the U.S., and it focuses on developing treatments for patients primarily in the United States and other global markets. Waltham is part of the Boston-Cambridge biotech hub, providing access to talent and research resources.

Spyre Therapeutics' pipeline includes several monoclonal antibody programs. SPY001 is a humanized anti-a4ß7 integrin antibody in phase-2 for ulcerative colitis and Crohn's disease. SPY002 and SPY072 are anti-TL1A antibodies designed to block tumor necrosis factor-like ligand 1A. SPY003 targets interleukin-23 (IL-23) and is also in phase-2. Additionally, the company is developing combination therapies: SPY120 (anti-a4ß7 + anti-TL1A), SPY130 (anti-a4ß7 + anti-IL-23), and SPY230 (anti-TL1A + anti-IL-23). These combinations aim to improve efficacy by simultaneously blocking multiple inflammatory pathways. All candidates are in clinical or preclinical stages, and none have received regulatory approval yet.